Journey Medical Corp (DERM)
5.15
+0.07
(+1.38%)
USD |
NASDAQ |
Nov 15, 16:00
5.00
-0.15
(-2.91%)
After-Hours: 20:00
Journey Medical Research and Development Expense (Quarterly): 0.913M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 0.913M |
| March 31, 2024 | 7.884M |
| December 31, 2023 | 1.505M |
| September 30, 2023 | 2.229M |
| June 30, 2023 | 1.774M |
| March 31, 2023 | 2.033M |
| December 31, 2022 | 4.256M |
| September 30, 2022 | 2.812M |
| June 30, 2022 | 2.609M |
| Date | Value |
|---|---|
| March 31, 2022 | 1.266M |
| December 31, 2021 | 1.992M |
| September 30, 2021 | 0.794M |
| June 30, 2021 | 13.77M |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Jun 2020
13.77M
Maximum
Jun 2021
2.579M
Average
1.774M
Median
Jun 2023
Research and Development Expense (Quarterly) Benchmarks
| Fortress Biotech Inc | 12.67M |
| Heron Therapeutics Inc | 4.432M |
| Eton Pharmaceuticals Inc | 2.97M |
| Elutia Inc | 1.001M |
| NovaBay Pharmaceuticals Inc | 0.004M |